Mar. 30 at 1:46 PM
$APRE According to the YE25 balance sheet, total assets was
$15.93M. A
$30M capital injection almost triples the asset size. Some shorts focus solely on the change in the float, ignoring the significant capital injection. Institutional investors pay ~
$0.80 per pre-funded warrant. An additional 37.2M warrants have a strike price of
$0.683 per share, which may imply further proceeds of ~
$25.4M. Overall, assuming all warrants are eventually exercised, the average cost per share for institutional investors (IIs) would be around
$0.75 (please feel free to comment if I misinterpret what is written in the press release). Therefore, a level between
$0.75 and
$0.80 may be deemed an anchor level and the value that IIs attribute to it in the current circumstances, probably based on the evaluations involving the probability of trial successes. If the trial results are successful and the FDA grants approval, IIs' investment in the stock may prove notably profitable. (not advice, just inferences)
